Drotrecogin alfa (activated) in the subgroup of patients with multiple organ dysfunction (MOD) during a global, single-arm, open-label trial in adult patients with severe sepsis (ENHANCE): comparisons with PROWESS

Ítems similars

• The efficacy of Drotrecogin alfa (activated) during a global, single-arm, open-label trial in adult patients with severe sepsis (ENHANCE): comparisons with PROWESS
  per: Vincent, J, et al.
  Publicat: (2004)
• The incidence of serious bleeding events in a global, single-arm, open-label trial of Drotrecogin alfa (activated) in adult patients with severe sepsis (ENHANCE): comparisons with PROWESS
  per: Beale, R, et al.
  Publicat: (2004)
• Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis
  per: Laterre, Pierre-François, et al.
  Publicat: (2008)
• Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated)
  per: Levy, Howard, et al.
  Publicat: (2005)
• Extended drotrecogin alfa (activated) therapy in patients with persistent requirement for vasopressor support after 96-hour infusion with commercial drotrecogin alfa (activated)
  per: Dhainaut, J, et al.
  Publicat: (2008)